The role of stress kinases in metabolic disease.
Ivana NikolicMagdalena LeivaGuadalupe SabioPublished in: Nature reviews. Endocrinology (2020)
Obesity is a health condition that has reached pandemic levels and is implicated in the development and progression of type 2 diabetes mellitus, cancer and heart failure. A key characteristic of obesity is the activation of stress-activated protein kinases (SAPKs), such as the p38 and JNK stress kinases, in several organs, including adipose tissue, liver, skeletal muscle, immune organs and the central nervous system. The correct timing, intensity and duration of SAPK activation contributes to cellular metabolic adaptation. By contrast, uncontrolled SAPK activation has been proposed to contribute to the complications of obesity. The stress kinase signalling pathways have therefore been identified as potential targets for the development of novel therapeutic approaches for metabolic syndrome. The past few decades have seen intense research efforts to determine how these kinases are regulated in a cell-specific manner and to define their contribution to the development of obesity and insulin resistance. Several studies have uncovered new and unexpected functions of the non-classical members of both pathways. Here, we provide an overview of the role of SAPKs in metabolic control and highlight important discoveries in the field.
Keyphrases
- insulin resistance
- metabolic syndrome
- adipose tissue
- skeletal muscle
- high fat diet induced
- high fat diet
- polycystic ovary syndrome
- heart failure
- type diabetes
- weight loss
- healthcare
- sars cov
- public health
- uric acid
- coronavirus disease
- cardiovascular risk factors
- squamous cell carcinoma
- cardiovascular disease
- stem cells
- transcription factor
- magnetic resonance imaging
- risk assessment
- body mass index
- endoplasmic reticulum stress
- magnetic resonance
- squamous cell
- glycemic control
- risk factors
- induced apoptosis
- computed tomography
- physical activity
- human health
- health information
- case control
- acute heart failure